LVLPs are non-replicative, derived from lentiviral components, offering safe, transient, high-capacity delivery for large payloads with high editing efficiency. The service supports gene therapy and transient expression programs via non-integrating packaging and pseudotyping.
Creative Biolabs' service provides controlled delivery, mitigates integrating vector risks, delivers to diverse cells (including non-dividing ones), and offers tailored functional LVLPs for expression, gene editing, and vaccine development.
Discover How We Can Help - Request a Consultation
Creative Biolabs' LVLPs are based on a refined packaging mechanism. They utilize the structural proteins (primarily Gag and often the envelope glycoprotein for cell targeting/tropism, such as VSV-G) to form a protective nanovesicle. Crucially, the packaging system is engineered to be deficient in or exclude the viral reverse transcriptase and integrase components (Pol). When the LVLP transduces a target cell, the payload (e.g., mRNA or RNP) is released into the cytoplasm. Unlike conventional lentiviruses, the payload cannot be reverse transcribed into DNA or integrated into the host genome. The delivered mRNA is directly translated into the target protein (for transient effect), or the RNP acts immediately, ensuring the therapeutic or editing activity is short-lived and non-permanent.
Our systematic workflow is designed for transparency and optimal product quality, providing a comprehensive and detailed explanation for each point suitable for visualization as a flowchart.
| Stage | Key Steps Involved |
|---|---|
| Project Initiation & Design | Required Starting Materials: Client provides the sequence for the target nucleic acid cargo (e.g., mRNA, non-coding RNA, or sgRNA sequence), the desired pseudotype (e.g., VSV-G, or a specific envelope sequence for tropism), and target cell line characteristics (dividing/non-dividing). |
| Plasmid Construction & Production | Custom engineering of the transfer vector incorporates the non-integrating elements (such as integrase-defective mutations or the Gag-only packaging signal) and the target payload. Large-scale, high-quality preparation of all necessary packaging and transfer plasmids. |
| LVLP Production & Assembly | Co-transfection of packaging cells (typically optimized HEK293T cells) with the engineered plasmids. LVLP particles self-assemble in the producer cells. The supernatant containing the crude LVLPs is harvested. |
| Concentration & Purification | The crude harvest undergoes tangential flow filtration (TFF) and/or ultracentrifugation (e.g., sucrose gradient or cushioned) for the removal of residual contaminants and concentration of the viral-like particles. |
| Quality Control & Titer Assessment | Rigorous functional and physical quality control. Physical titer is measured via p24 ELISA, and functional efficiency is determined by transducing target cells and measuring payload delivery (e.g., through qRT-PCR for packaged RNA or reporter gene expression). |
Estimated Timeframe: The typical timeframe for this service ranges from 8 to 12 weeks, depending on the complexity of the cargo (e.g., large mRNA sequences requiring de novo synthesis) and the required level of purification (e.g., research-grade vs. preclinical-grade).
Experience the Creative Biolabs Advantage - Get a Quote Today
One-stop LVLP development service from pre-development design, prototype production, to preclinical-scale supply, covering your full research and development cycle.
Customized LVLP solutions tailored to your specific cargo (mRNA, RNP, even large modified mRNA over 10,000 nucleotides) and target cell types (e.g., hard-to-transduce primary hematopoietic stem cells).
Proprietary Gag-Only and integrase-defective systems to ensure non-integrating, high-safety transient gene delivery, reducing off-target effects and cellular toxicity.
Optimized pseudotyping technology to drastically improve transduction efficiency for diverse cell lines, addressing your transduction challenges.
High-titer, high-purity LVLP production with clear, detailed quality control (QC) reports, verifying payload packaging efficiency and particle integrity.
Well-established quality system compliant with GMP principles, integrating Quality-by-Design (QbD) to guarantee batch-to-batch consistency.
End-to-end technical support, from payload compatibility analysis to process optimization, to accelerate your gene therapy and genome engineering research progress.
LVLPs offer a distinct advantage over LNPs by leveraging the highly evolved viral machinery for cellular entry, often resulting in superior transduction efficiency, especially in hard-to-transduce primary cells. While LNPs are excellent for systemic delivery, LVLPs can be pseudotyped for more specific targeting. We recommend a brief consultation to assess your target cell type and delivery goals so we can guide you to the optimal platform.
Our system is engineered with multiple safety layers, employing a non-integrating, self-inactivating (SIN) vector design and often utilizing a specialized Gag-Only packaging strategy that entirely excludes key genes (like Pol/Rev/Tat) necessary for viral replication or integration. This provides an extremely low risk profile compared to older lentiviral systems. All final lots undergo rigorous testing to ensure the absence of RCL.
Absolutely. Our Custom LVLP Development Service specializes in handling novel and complex payloads. We use optimized proprietary packaging sequences compatible with various RNA modifications and large RNP payloads. Please provide us with the sequence details and modifications in your initial inquiry, and we will tailor the optimal vector system to ensure maximum packaging efficiency.
Since LVLPs do not integrate, their episomal DNA is subject to degradation and dilution in dividing cells, which inherently leads to transient—not permanent—expression. While expression per vector copy can sometimes be lower than fully integrated vectors, we compensate by using optimized, strong promoters and high-titer LVLP production to ensure high initial expression levels, which is precisely what is needed for applications like transient gene editing.
That's a great question, and it's where our expertise comes in. Simply provide us with the details of your target cell line (e.g., species, tissue origin, in vitro or in vivo use). We offer screening services using various envelope pseudotypes (such as different VSV-G variants or modified envelopes) to experimentally determine the most effective LVLP for your specific cell tropism, ensuring your project starts on the right footing.
The service offers cutting-edge, high-safety transient gene delivery solutions, addressing efficient non-integrating payload transfer needs in advanced gene therapy and genome engineering research. It uses a streamlined process with proprietary Gag-Only and integrase-defective systems to produce high-quality LVLPs. These LVLPs are tailored for complex mRNA and RNP cargo delivery, with superior safety and efficacy vs. integrating vectors, helping accelerate research without compromising safety or efficiency.
Contact Our Team for More Information and to Discuss Your Project
| Cat. No | Product Name | Promoter |
|---|---|---|
| CAT#: GTVCR-WQ001MR | IVTScrip™ pT7-mRNA-EGFP Vector | T7 |
| CAT#: GTVCR-WQ002MR | IVTScrip™ pT7-VEE-mRNA-EGFP Vector | T7 |
| CAT#: GTVCR-WQ003MR | IVTScrip™ pT7-VEE-mRNA-FLuc Vector | T7 |
| CAT#: GTVCR-WQ87MR | IVTScrip™ pT7-VEE-mRNA-Anti-SELP, 42-89-glycoprotein Vector | T7 |
| Cat. No | Product Name | Type |
|---|---|---|
| CAT#: GTTS-WQ001MR) | IVTScrip™ mRNA-EGFP (Cap 1, 30 nt-poly(A)) | Reporter Gene |
| CAT#: GTTS-WK18036MR | IVTScrip™ mRNA-Human AIMP2, (Cap 1, Pseudo-UTP, 120 nt-poly(A)) | Enzyme mRNA |
| (CAT#: GTTS-WQ004MR) | IVTScrip™ mRNA-Fluc (Cap 1, 30 nt-poly(A)) | Reporter Gene |
| (CAT#: GTTS-WQ009MR) | IVTScrip™ mRNA-β gal (Cap 1, 30 nt-poly(A)) | Reporter Gene |
